Novel veterinary oncologic treatments and diagnostics

April 23, 2022
dvm360 logo

This article was written by Julia Burke and published in dvm360.

---

Craig A. Clifford, DVM, MS, DACVIM (Oncology), offered an overview of the latest treatment and diagnostic tools accelerating veterinary oncology

Cancer is one of the leading causes of death in dogs over 10 years old, with 50% of canines developing the disease.1 At the Fetch dvm360® conference held in Charlotte, North Carolina, Craig A. Clifford, DVM, MS, DACVIM (Oncology), detailed innovative products and technology to provide the best care and quality of life for oncologic patients.

ImpriMed chemotherapy sensitivity assay

According to Clifford, ImpriMed offers a precision medicine service to predict a patient’s response to a drug by using artificial intelligence (AI) algorithms that combine immunophenotyping data, live cell-based chemosensitivity results and a patient’s clinical data.2 Veterinarians submit patients’ samples by using a fine needle aspiration biopsy and the test kit provided. Within just 7 days, they receive AI driven, personalized, anti-cancer drug response predictions.

ImpriMed analyzes the live cells and indicates the chance a patient will respond to a specific drug and compares your case to the average dog. It also tells veterinarians the timeline of when the patient will likely respond to treatment and can predict how a patient will do overall regarding B-cells versus T-cells, high prediction versus low prediction scores, etc.

“It can help us choose drugs that will work or potentially not choose drugs that we think are going to be less effective,” Clifford said. “It’s truly a first step with personalized medicine...the genetics of the cancer is actually helping guide how we’re treated on the physician-based side, and we’re getting there now in veterinary medicine.”

Clifford noted ImpriMed services should be considered for both naïve or relapsed patients to2:

  • See accurate immunophenotyping and chemosensitivity assays to better support treatment (especially for atypical lymphomas that there is less research on)
  • Detect possible cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) failure patients
  • Predict anti-cancer therapies for patients with comorbidities or contraindications
  • Provide single agent therapy for pet parents with financial limits
  • Find the ideal option with fewest doses/month or a dosing schedule when patient lives far away

Laverdia CA-1

Laverdia CA-1 is an oral anti-cancer targeted treatment for all forms of lymphoma that utilizes selective inhibitor of nuclear export (SINE) technology that is also used in human medicine. Clifford explained that during a study analyzing quality of life when taking the drug, most owners felt their pet maintained a good quality of life even when the disease progressed, so a significant number of patients remained on the drug because they felt content.2

“I feel more likely [Laverdia CA-1] is going to be a primary care drug. I think oncologists, we’re going to try and figure out where we put it in the protocols, but I really do see it as a bridge to getting to treatment or in the cases where the owner doesn’t want to go further,” Clifford said.

“That means more cases are going to be treated and there are maybe some cases that have a greater response, and the owner then elects to go for treatment and that’s wonderful too because then you know that dog is going to likely live longer and that wouldn’t have happened if we didn’t have that bridge to get there,” he continued.

Some adverse effects of Laverdia CA-1 include anorexia, weight loss, vomiting, diarrhea, and vomiting so it is important to do weight assessments during follow-up visits. It is to be given at 1.25/mg/kg twice weekly to a minimum dose of 1 mg/kg twice per week with at least 72 hours between doses.2 It is available in 3 doses: 2.5 mg per tablet, 10 mg per tablet, and 50 mg per tablet.

Clifford noted that there is limited data currently available surrounding Laverdia CA-1, so it is difficult to draw too many conclusions. Thus, there is going to be be a learning curve with it and investigator driven trials must be completed to determine which cases to use it for, how to adjust the dose, which chemotherapy drugs it may be best combined with, plus more.

OncoK9 liquid biopsy test

OncoK9 is a noninvasive liquid biopsy test using a simple blood draw designed for early screening of canine cancer. Using cutting-edge technology, it is highly accurate in finding certain genetic sequences associated with 30 types of cancer to indicate if a patient has a risk developing it.

“Using next generation sequencing, [OncoK9] is considered high end. What they have been able to find is certain genetic sequences that are common to many cancers so you can imagine if it's positive, there is a high probability the patient has cancer," Clifford shared. “It’s not affected by inflammation; it’s not affected by if the patient ate or anything like that; those don’t play a role in it."

Clifford added it is ideal as an annual screening test for dogs at higher risk of cancer (ie, those over 8 years old and predisposed breeds). Some breeds predisposed to cancer2 include golden retrievers, German shepherds, Boxers, Bernese Mountain dogs, and more. OncoK9 also aids as a diagnostic test for canines in which cancer is suspected.

“All of these groups have come out and said what we already know: wouldn’t it be nice if we could diagnose [cancer] earlier? Meaning, we can find the cancer before it’s metastasized if its osteosarcoma or angiosarcoma, wouldn’t it be great to catch it when it’s at its lowest point? That’s our greatest chance to impact overall survival,” said Clifford.

Takeaways

Summarizing his points to conclude the lecture, Clifford stated ImpriMed is a novel tool for select cases and may change how atypical lymphoma is treated. Additionally, Laverdia CA-1 is a convenient and effective oral treatment option and post-market research will determine its niche, plus the OncoK9 liquid biopsy test is best for older or predisposed breeds and in circumstances where cancer is a concern.

References

  1. Davis BW, Ostrander EA. Domestic dogs and cancer research: a breed-based genomics approach. ILAR J. 2014;55(1):59-68. doi:10.1093/ilar/ilu017
  2. Clifford CA. Recent advancements in oncology. Presented at Fetch dvm360® conference; Charlotte, North Carolina. April 22-24, 2022.


In the News

How Artificial Intelligence Is Revolutionising Cancer Care for Pets

Pets Magazine
Learn More →

Artificial Intelligence Takes on Cancer: The Only AI Dr. Karyn Doesn’t Hate

Dogster
Learn More →

Comparative Oncology: Advances in Cancer Care from Pets to Humans

Pharmacy Times
Learn More →

Cancer Treatment Gets Personal: How Artificial Intelligence Is Taking the Guesswork Out of Common Canine Cancers

Dogster
Learn More →

Ilona Holcomb on How ImpriMed’s AI is Transforming Cancer Treatment for Pets and Humans

Biopharma Boardroom
Learn More →

From Dogs to Humans: AI-Powered Drug Response Prediction Technology Demonstrates Improved Clinical Outcomes in Oncology

Pharmacy Times
Learn More →

ImpriMed unveils cancer treatment forecast technology

MobiHealthNews
Learn More →

New research evaluates flow cytometry and PARR as diagnostic support for feline lymphoma

American Animal Hospital Association NEWStat®
Learn More →

Cell-sizing method for high-accuracy feline lymphoma characterisation in veterinary sciences

Veterinary Practice
Learn More →

Flow cytometry and clonality evaluation are effective for characterizing feline lymphoma

DVM360
Learn More →

ImpriMed: Providing Personalized Medicine For Pets With Blood Cancer Diseases In A $1+ Billion Market

Pulse 2.0
Learn More →

New AI Tool Guides Canine Cancer Treatment

Today's Veterinary Business
Learn More →

Artificial intelligence poised to transform veterinary care

AVMA News
Learn More →

New AI service offers personalized drug response predictions for canine patients with cancer

DVM360
Learn More →

Dog cancer treatment ImpriMed aims to expand its AI technology into human oncology

TechCrunch
Learn More →

ImpriMed’s Transformative, Personal Approach to Canine Cancer Treatment

USA Today
Learn More →

Data Science Can Markedly Improve Cancer Treatment Outcomes — ImpriMed Shows You How

Innovative Veterinary Care Journal
Learn More →

How ImpriMed Can Help Increase Cancer Remissions, Grow Your Reputation and Level Up Your Revenue

Innovative Veterinary Care Journal
Learn More →

ImpriMed: A Breath of Fresh Air for Traditionally Onerous Cancer Treatment Journeys

Innovative Veterinary Care Journal
Learn More →

ImpriMed: Revolutionizing Canine Cancer Treatment with Precision and Personalization

International Business Times
Learn More →

New AI Technology From ImpriMed Helps Improve Cancer Treatment Success Rates in Your Practice…and Fosters Better Relationships

Innovative Veterinary Care Journal
Learn More →

The latest and greatest in canine oncology treatment

DVM360
Learn More →

Get Rid of Your Cancer Treatment Frustrations

Innovative Veterinary Care Journal
Learn More →

Meet the 7 startups Mayo Clinic just welcomed to its AI accelerator

MedCity News
Learn More →

Be sure to improve your cancer treatment outcomes

Innovative Veterinary Care Journal
Learn More →

Early leukemia and lymphoma remissions in cats and dogs

Innovative Veterinary Care Journal
Learn More →

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 3)

One Million by One Million
Learn More →

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 2)

One Million by One Million
Learn More →

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 1)

One Million by One Million
Learn More →

Technological advancement makes cancer treatment easier

Innovative Veterinary Care Journal
Learn More →

AI’s Computing Power Could Make Fusion Energy Practical

Lifewire
Learn More →

Don't Guess Your Pet's Condition, Treat It with ImpriMed

Startup to Follow
Learn More →

Interview with ImpriMed CEO & Co-Founder Sungwon Lim

IdeaMensch
Learn More →

This Test Might Make All The Difference When Fighting Lymphoma

Canine Cancer Alliance
Learn More →

ImpriMed: Fighting Cancer — From Dogs To Humans

Startup Thread
Learn More →

At Pear demo day, a who’s who of VCs, and plenty of fresh ideas

TechCrunch
Learn More →